糖尿病肾病患者尿蛋白的药物治疗研究.docVIP

糖尿病肾病患者尿蛋白的药物治疗研究 】目的深入研宄糖尿病？I病患者的治疗药物及效果。方法80 例糖尿病肾病患者，随机分成研究组与参照组，每组40例。研究组 患者采用罗格列酮与厄贝沙坦治疗，参照组患者采用二甲双胍与氨氯 地平治疗。记录并比较两组患者治疗前后微量尿蛋白、尿蛋白、血糖、 血压等变化情况。结果治疗前，研究组微量尿蛋G为(229.7±208.4) mg/L、尿蛋白为(1.1±0.9) g/24h；参照组分别为(226. 3±231. 7) mg/L、(1.2±1.0) g/24 h。治疗后，研究组微量尿蛋白为(126.9 ±108.3) mg/L、尿蛋白为(0.5土 ，供学习和研宄 使用， 和著作权归原 所有， 己 如果需耍分享， 请保留本段说明。 0.4) g/24 h;参照组分别为(158. 4± 129.6) mg/L、(0. 7±0. 6) g/24 h。治疗前两组微量尿蛋白、尿蛋白水平比较差异无统计学意义 (P0. 05)；治疗后两组患者微量尿蛋白、尿蛋白均下降，且研究组 下降幅度大于参照组，差异具有统计学意义(P0. 05)。治疗前，两 组患者血压、血糖水平比较差异无统计学意义(P〉0. 05)；治疗后，两 组患者血压、血糖均有所下降，且研究组下降幅度大于参照组，差 异具有统计学意义（P〈o. 05）。结论罗格列酮与厄贝沙坦能将尿蛋白、 血糖、血压等指标控制在正常范围内，有效缓解临床表现，提高预 后效果，应推广使用。 关键词】糖尿病肾病；尿蛋白；药物治疗；效果 D0I： 10.14163/j.cnki.11-5547/r. 2017. 05. 048 Research of drug therapy for urine protein in diabetic nephropathy patients ZHANG Xiao-dong. Department of Nephrology, First Auto Work General Hospital， Changchun 130011， China [Abstract] Objective To thoroughly research drug and effect in treatment of diabetic nephropathy patients. Methods A total of 80 patients with diabetic nephropathy were randomly divided into research group and control group, with 40 cases in each group. The research group received rosiglitazonc and irbesartan for treatment, and the control group received metformin and amiodipine for treatment. Records and comparison were made on changes in urine microprotein, urine protein, blood glucose and blood pressure before and after treatment between the two groups. Results Before treatment, the research group had urine microprotein as (229. 7±208. 4) mg/L and urine protein as (1.1 ±0.9) g/24 h, which were respectively (226. 3±231. 7) mg/L and (1.2±1.0) g/24 h in the control group. After treatment, the research group had urine microprotein as (126. 9± 108. 3) mg/L and urine protein as (0. 5 ±0.4) g/24 h, which were respectively (158. 4± 129. 6) mg/L and (0.7 ±0.6) g/24 h in the control group. There was no statistically significant difference of urine microprotein and urine protein before treatment between the two